What have we learnt from the rosiglitazone saga?

BMJ

Volumn 342, Issue 7799, 2011, Pages 666-

  Montori, Victor M ^a   Shah, Nilay D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

CARDIOVASCULAR DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; EDITORIAL; FRACTURE; GLYCEMIC CONTROL; HEALTH CARE SYSTEM; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 79953168441     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d1354     Document Type: Editorial

References (12)

1. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011;342:d1309.
2. Nissen SE. The rise and fall of rosiglitazone. Eur Heart J 2010;31:773-6.
3. Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA warning - geographic variation in the use of rosiglitazone. N Engl J Med 2010;363:2081-4.
4. Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med 2009;150:803-8.
5. Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010;53:2079-85.
6. Pogach L, Aron DC. Sudden acceleration of diabetes quality measures. JAMA 2011;305:709-10.
7. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 2010;31451-61.
8. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168:2070-80.
9. Top 15 US pharmaceutical products by sales. 2009. www.imshealth.com/ portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a /?vgnextoid=4e260fc5b45b7210VgnVCM100000ed152ca2RCRD&cpsextcurrchannel=1.
10. Alazraki M. As diabetes explodes, big pharma is gearing up. Daily Finance 2011. www.dailyfinance.com/story/investing/diabetes-big-pharma-gears-up/ 19816863/.
11. Mullan RJ, Montori VM, Shah ND, Christianson TJ, Bryant SC, Guyatt GH, et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med 2009;169:1560-8.
12. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(suppl 1):S11-61.